
So-Young International SY
$ 2.69
0.56%
Annual report 2024
added 01-17-2026
So-Young International Income Statement 2011-2026 | SY
Annual Income Statement So-Young International
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
63.5 M | 97.1 M | 100 M | 196 M | 952 M | 721 M | 29.7 M | 32.5 M | - | - | - | - | - | - |
Shares |
79.4 M | 77.6 M | 82.7 M | 81.7 M | 81.5 M | 59.4 M | 24.6 M | 26.9 M | - | - | - | - | - | - |
Historical Prices |
0.8 | 1.25 | 1.21 | 2.4 | 11.7 | 12.2 | - | - | - | - | - | - | - | - |
Net Income |
-590 M | 21.3 M | -65.6 M | -8.37 M | 5.81 M | 177 M | 55.1 M | 17.2 M | -81 M | - | - | - | - | - |
Revenue |
- | - | - | -1.52 M | 1.29 B | 1.15 B | 617 M | 259 M | 49.1 M | - | - | - | - | - |
Cost of Revenue |
568 M | 544 M | 393 M | 328 M | 212 M | 199 M | 91.6 M | 44.8 M | - | - | - | - | - | - |
Gross Profit |
899 M | 954 M | 865 M | 1.36 B | 1.08 B | 953 M | 526 M | 215 M | 23.9 M | - | - | - | - | - |
Operating Income |
-624 M | -61 M | -103 M | -32.6 M | -56.7 M | 145 M | 49.1 M | 24.8 M | - | - | - | - | - | - |
Interest Expense |
- | - | - | 12 M | 8.92 M | 34.8 M | 990 K | -12.2 M | - | - | - | - | - | - |
EBITDA |
-579 M | -15 M | -55.7 M | -2.49 M | -42.6 M | 151 M | 50.8 M | 25.4 M | -73.7 M | - | - | - | - | - |
Operating Expenses |
- | - | - | 1.4 B | 1.14 B | 808 M | 477 M | 190 M | 98.2 M | - | - | - | - | - |
General and Administrative Expenses |
- | - | - | 252 M | 184 M | 631 M | 382 M | 29.7 M | 18 M | - | - | - | - | - |
All numbers in CNY currency
Quarterly Income Statement So-Young International
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
- | - | - | - | - | - | - | - | 70.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in CNY currency
The income statement is one of the three key financial reports of a company So-Young International (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Health information services industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Cerner Corporation
CERN
|
- | - | $ 27.9 B | ||
|
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | ||
|
Covetrus
CVET
|
- | - | $ 2.94 B | ||
|
Change Healthcare
CHNG
|
- | - | $ 9.03 B | ||
|
Accolade
ACCD
|
- | 0.29 % | $ 206 M | ||
|
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | ||
|
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | ||
|
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | ||
|
Evolent Health
EVH
|
$ 3.93 | 4.11 % | $ 368 M | ||
|
Akerna Corp.
KERN
|
- | - | $ 161 M | ||
|
Health Catalyst
HCAT
|
$ 2.2 | -4.76 % | $ 132 M | ||
|
HealthStream
HSTM
|
$ 21.27 | -2.48 % | $ 646 M | ||
|
iCAD
ICAD
|
- | - | $ 102 M | ||
|
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | ||
|
HealthEquity
HQY
|
$ 84.42 | -1.11 % | $ 7.22 B | ||
|
American Well Corporation
AMWL
|
$ 4.64 | -2.52 % | $ 69.6 M | ||
|
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | ||
|
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | ||
|
GoodRx Holdings
GDRX
|
$ 2.6 | -3.17 % | $ 1 B | ||
|
OptimizeRx Corporation
OPRX
|
$ 11.92 | -1.89 % | $ 204 M | ||
|
Omnicell
OMCL
|
$ 49.14 | -2.73 % | $ 2.26 B | ||
|
Premier
PINC
|
- | - | $ 2.33 B | ||
|
Progyny
PGNY
|
$ 25.33 | 3.3 % | $ 2.17 B | ||
|
Phreesia
PHR
|
$ 15.64 | -4.58 % | $ 853 M | ||
|
R1 RCM
RCM
|
- | - | $ 3.81 B | ||
|
Zhongchao
ZCMD
|
$ 0.48 | -3.92 % | $ 2.5 M | ||
|
Schrödinger
SDGR
|
$ 16.37 | -2.5 % | $ 1.19 B | ||
|
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | ||
|
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | ||
|
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | ||
|
10x Genomics
TXG
|
$ 22.12 | 7.77 % | $ 2.59 B | ||
|
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | ||
|
Teladoc Health
TDOC
|
$ 6.08 | -3.18 % | $ 1.04 B | ||
|
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | ||
|
Veeva Systems
VEEV
|
$ 215.95 | -2.82 % | $ 34.7 B | ||
|
SCWorx Corp.
WORX
|
$ 0.18 | -2.23 % | $ 263 K |